According to Gram Research analysis, Aldixyl, a derivative of Lorenzo’s Oil combined with dietary changes, significantly slowed nerve damage progression in women carrying X-linked adrenoleukodystrophy. In a study of 36 women followed for nearly six years, those receiving Aldixyl plus diet showed 2.26 points less progression on nerve damage scales compared to diet-only women, while also reducing harmful blood fatty acids by 0.40 units. The treatment preserved adrenal function and showed an acceptable safety profile, though larger studies are needed to confirm these promising findings.
Researchers studied a special oil-based treatment called Aldixyl combined with diet changes in women who carry a rare genetic condition called X-linked adrenoleukodystrophy. This condition can cause nerve damage and movement problems. In a study of 36 women followed for nearly six years, those who received the oil treatment plus dietary guidance showed slower progression of nerve damage compared to those who only changed their diet. The treatment also helped reduce harmful fatty acids in the blood. While results are promising, doctors say larger studies are needed to confirm these findings before making it standard treatment.
Key Statistics
A 2026 cohort study of 36 women carriers of X-linked adrenoleukodystrophy found that Aldixyl combined with dietary interventions reduced neurological progression by 2.26 points on the Adult ALD Clinical Score over a median follow-up of 69 months compared to diet alone.
Aldixyl treatment was associated with sustained reduction of very-long-chain fatty acids by 0.40 units in women with X-ALD, according to a 2026 study of 36 patients at a specialized children’s hospital.
In a 2026 study of 36 female X-ALD carriers, women receiving Aldixyl plus diet showed 1.03 points less progression on the Expanded Disability Status Scale over nearly six years compared to those receiving diet only.
A 2026 analysis of 36 women with X-linked adrenoleukodystrophy found that Aldixyl treatment preserved adrenal function while showing only mild, uncomplicated decreases in platelet count as a safety concern.
The Quick Take
- What they studied: Whether a special oil treatment called Aldixyl, combined with dietary changes, could slow down nerve damage in women who carry a genetic condition that affects the nervous system.
- Who participated: Thirty-six women with an average age of 41.6 years who carry the X-ALD gene. About one-third had already developed nerve symptoms at the start of the study. Twenty women received the oil treatment plus diet guidance, while sixteen received diet guidance alone.
- Key finding: Women who received Aldixyl plus diet changes showed significantly slower nerve damage progression over nearly six years compared to diet-only women. The treatment also reduced harmful fatty acids in their blood by about 0.40 units.
- What it means for you: For women who carry this rare genetic condition, this treatment combination may help slow nerve damage progression. However, this is early-stage research, and larger studies are needed before doctors can recommend it as standard care. Talk to your neurologist about whether this might be appropriate for you.
The Research Details
Researchers looked back at medical records of women treated at a children’s hospital in Italy between 2001 and 2025. They compared two groups: women who received Aldixyl (a special oil derived from Lorenzo’s Oil) plus specific dietary recommendations, and women who received only dietary guidance. They measured nerve damage using three different tests: a scoring system for nerve symptoms, a disability scale, and a timed walking test. They also measured harmful fatty acids in the blood and checked how well the adrenal glands (small glands that produce important hormones) were working.
This type of study, called a retrospective cohort study, looks at what already happened to patients rather than randomly assigning people to treatments. The researchers followed patients for a median of 69 months (about 5.75 years), which is long enough to see meaningful changes in a slow-progressing disease.
The study was conducted at a single hospital, which means all patients received care from the same medical team using consistent methods. However, the two groups were not perfectly matched at the start: the Aldixyl group was older and had more nerve damage initially, which could affect the results.
This research matters because X-linked adrenoleukodystrophy in women carriers is a serious condition with limited treatment options. Most current treatments focus on managing symptoms rather than slowing disease progression. By looking at real patient outcomes over many years, researchers can see whether a treatment actually works in everyday medical practice, not just in controlled laboratory conditions. The long follow-up period allows researchers to detect slow changes that might not appear in shorter studies.
Strengths of this study include the long follow-up period (nearly six years), the use of multiple measurement tools to assess nerve damage, and careful monitoring of safety. Limitations include the small sample size, the fact that it was conducted at only one hospital, and that patients were not randomly assigned to treatment groups. The treatment group was older and more severely affected at baseline, which could bias results in either direction. The study is retrospective, meaning researchers relied on medical records rather than prospectively collecting data. These factors mean the findings are promising but need confirmation in larger, randomized controlled trials before becoming standard medical practice.
What the Results Show
Over the median follow-up period of 69 months, women receiving Aldixyl plus diet showed significantly slower nerve damage progression compared to the diet-only group. Using the Adult ALD Clinical Score (a standard measure of nerve symptoms), the Aldixyl group showed 2.26 points less progression than the diet group. On the Expanded Disability Status Scale (which measures overall disability), the Aldixyl group showed 1.03 points less progression.
The treatment was associated with sustained reduction in very-long-chain fatty acids (harmful fats that accumulate in this disease), with an average reduction of 0.40 units. These fatty acids are the hallmark of X-ALD and are thought to drive nerve damage, so reducing them may help protect the nervous system.
Adrenal function remained stable in both groups, meaning the treatment did not harm the adrenal glands’ ability to produce essential hormones. Metabolic parameters (measures of how the body processes nutrients) also stayed normal. The only safety concern was a mild, uncomplicated decrease in platelet count (cells that help blood clot), which did not cause bleeding problems.
Interestingly, the timed walking test (T25-FW) did not show significant differences between groups, suggesting that while nerve damage progression slowed, walking speed may be affected by other factors or may require longer to show improvement.
The study found that baseline characteristics differed between groups: the Aldixyl group was older (mean age 43.8 vs. 39.1 years) and more neurologically impaired at baseline (AACS score 3.45 vs. 0.38). This means the group receiving treatment started in worse condition, which actually makes the slower progression more impressive. If the treatment group had started healthier, the results might have been even more favorable. The mild decrease in platelet count was consistent across the treatment group but did not progress to dangerous levels or cause clinical problems.
This study builds on decades of research into Lorenzo’s Oil, a famous treatment developed in the 1980s for X-ALD. Aldixyl is a newer derivative of Lorenzo’s Oil designed to be more effective. Previous studies showed that Lorenzo’s Oil could reduce very-long-chain fatty acids but had mixed results on slowing disease progression. This new study suggests that combining Aldixyl with dietary interventions may be more effective than diet alone. However, most previous research focused on childhood-onset X-ALD, while this study examines female carriers, a population that has received less research attention. The findings suggest that female carriers may benefit from similar approaches as affected males.
The study has several important limitations. First, it included only 36 patients from a single hospital, which is a small sample size. Results from small studies may not apply to larger populations. Second, patients were not randomly assigned to treatment groups, so differences between groups (like age and baseline severity) could affect results. Third, the study is retrospective, meaning researchers relied on medical records that may be incomplete or inconsistent. Fourth, the treatment group was older and more severely affected at baseline, which could bias results. Fifth, there was no control group receiving a placebo, so some improvement might be due to natural disease variation or other factors. Finally, the study was conducted in Italy and may not apply to different populations or healthcare settings.
The Bottom Line
For women who are carriers of X-linked adrenoleukodystrophy and have developed neurological symptoms, Aldixyl combined with dietary interventions appears to slow nerve damage progression based on this research. However, confidence in this recommendation is moderate because the study is small and not randomized. Before starting this treatment, discuss with your neurologist whether it is appropriate for your specific situation. The treatment appears safe based on this study, with only mild side effects. Larger, randomized controlled trials are needed to confirm these findings and establish clear treatment guidelines.
This research is most relevant to women who carry the X-ALD gene and have developed neurological symptoms like weakness, numbness, or movement problems. It may also be relevant to women who carry the gene but have no symptoms yet, as early treatment might prevent symptoms from developing. Family members of people with X-ALD should consider genetic testing to determine if they are carriers. This research is less immediately relevant to men with X-ALD, though similar treatments may eventually be studied in that population. Healthcare providers specializing in neurological or metabolic disorders should be aware of these findings.
Based on this study, meaningful slowing of nerve damage progression became apparent over several years of treatment. The median follow-up was 69 months (about 5.75 years). You should not expect immediate improvement in symptoms. Instead, the goal is to slow the rate at which nerve damage progresses. Some patients might notice stabilization of symptoms or slower worsening over 1 to 2 years, while others might not see obvious changes for several years. Regular monitoring with neurological exams and blood tests is important to track whether treatment is working.
Frequently Asked Questions
What is X-linked adrenoleukodystrophy and why does it affect women carriers?
X-linked adrenoleukodystrophy is a rare genetic condition where the body cannot properly break down certain fatty acids, causing them to accumulate and damage nerves. Women who carry one copy of the faulty gene can develop nerve damage over time, though usually less severely than men with two copies of the gene.
How does Aldixyl work to slow nerve damage in X-ALD?
Aldixyl is an oil-based treatment derived from Lorenzo’s Oil that helps reduce very-long-chain fatty acids in the blood. By lowering these harmful fatty acids, the treatment may reduce damage to nerve cells and slow the progression of neurological symptoms.
Is Aldixyl safe for long-term use in women with X-ALD?
Based on this study of 36 women followed for nearly six years, Aldixyl appears safe with an acceptable side effect profile. The only notable safety finding was mild, uncomplicated decreases in platelet count that did not cause bleeding problems. However, larger studies are needed to confirm long-term safety.
How long does it take to see benefits from Aldixyl treatment?
This study followed patients for a median of 69 months (about 5.75 years) to detect meaningful slowing of nerve damage progression. You should not expect immediate symptom improvement. Instead, the goal is to slow the rate of disease progression, which may become apparent over 1 to 2 years of consistent treatment.
Should I ask my doctor about Aldixyl if I am a female X-ALD carrier?
If you are a female X-ALD carrier with neurological symptoms, discuss Aldixyl with your neurologist. This research shows promising results, but larger studies are still needed. Your doctor can determine whether this treatment is appropriate for your specific situation and monitor your response.
Want to Apply This Research?
- Track neurological symptoms weekly using a simple scale: record any changes in weakness, numbness, balance problems, or fatigue on a 0-10 scale. Also track adherence to dietary recommendations and Aldixyl dosing daily. This creates a personal record to share with your neurologist at appointments.
- Users should set daily reminders to take Aldixyl at the prescribed time and log dietary adherence (such as avoiding high-fat foods or following specific nutritional guidelines). Create a weekly summary view showing symptom trends and medication compliance to motivate consistent behavior.
- Establish a monthly review where users compare their symptom scores to previous months to identify trends. Set quarterly goals to discuss with their neurologist, such as maintaining stable walking speed or preventing new symptoms. Use the app to schedule and prepare for neurological appointments, including a summary of tracked symptoms to bring to each visit.
This article summarizes research findings and is not medical advice. X-linked adrenoleukodystrophy is a serious rare genetic condition that requires specialized medical care. If you are a female carrier of X-ALD or have symptoms of this condition, consult with a neurologist or metabolic disease specialist before starting any treatment. The findings presented here are from a single-center retrospective study of 36 patients and require confirmation in larger, prospective, randomized controlled trials before becoming standard medical practice. Do not start, stop, or change any treatment based on this article without guidance from your healthcare provider.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.